StemCell Therapy

New Jersey, United States, The Personalized Medicine Market report 2020 provides a detailed impression, describe the product industry scope and the market expanded insights and forecasts up to 2027. It shows market data according to industry drivers, restraints and opportunities, analyzes the market status, the industry share, size, future Trends and growth rate of the market. The Personalized Medicine Market report is categorized by application, end user, technology, product / service types, and other, as well as by region. In addition, the report includes the calculated expected CAGR of chitosan acetate-market derivative from the earlier records of the Personalized Medicine Market, and current market trends, which are organized with future developments.

Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of10.67% from 2019-2026 and reachUSD 217.90 Billion by 2026.

Download full PDF example copy of Personalized Medicine Market report: (including Full Toc, list of tables and numbers, graph): https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=TDC&utm_medium=001

The report provides detailed coverage of the Personalized Medicine Market, including structure, definitions, applications, and Industry Chain classifications. The Personalized Medicine Market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunities and development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / export consumption, supply and demand, costs, industry share, policy, Price, Sales and gross margins.

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=TDC&utm_medium=001

Personalized Medicine Market forecast up to 2027, with information such as company profiles, product picture and specification, capacity production, price, cost, revenue, and contact information. Upstream raw materials and equipment as well as downstream demand analyses are also carried out. The Personalized Medicine Market size, development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and general research results are offered.

The Personalized Medicine Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=TDC&utm_medium=001

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

More:
Personalized Medicine Market is Thriving Worldwide 2020 | Trends, Growth and Profit Analysis, Forecast by 2027 - The Daily Chronicle

IRVING, Texas, Sept. 9, 2020 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian J. Brille, Vice Chairman of the Company, will participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference Thursday, Sept. 17, 2020, at 9:30 a.m. Eastern time.

Mr. Brille will provide an overview of Caris' business, along with its suite of market-leading molecular profiling offerings, and discuss recent corporate growth initiatives that position Caris to further extend its leadership reach in the market. Thomas Parker, Senior Vice President and Chief Financial Officer at Caris, will be available for Q&A.

Attendees who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Morgan Stanley representative.

About Caris Life SciencesCaris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome whole exome sequencing with 22,000 DNA genes, and MI Transcriptome whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.

Caris is also advancing precision medicine with Caris MAI (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Caris Pharmatech is changing the paradigm and streamlines the clinical trial process by assisting biopharma companies with accessing research-ready oncology sites for clinical trials. With over 200 research sites within the Caris Pharmatech JIT Oncology Network, biopharma companies can identify and enroll more patients, faster. Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. By implementing a Just-In-Time (JIT) Research System, site activation and patient enrollment is achievable within 14 days for pre-registered locations with pre-qualified patients.

Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

Investor Inquiries:Argot Partners [emailprotected]212-600-1902

Media Contact: Lindsey BailysGCI Health[emailprotected]212-798-9884

SOURCE Caris Life Sciences

Home

Excerpt from:
Caris Life Sciences Announces Participation in the 18th Annual Morgan Stanley Global Healthcare Conference - PRNewswire

SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Latest study released by Data Bridge Market Research on Pharma Clinical Trial Digitization Market research report 2020 comprises of several parameters which are thoroughly studied by the experts. This market report contains fundamental, secondary and advanced information related to the global status and trend, market size, sales volume, market share, growth, future trends analysis, segment and forecasts from 2020-2027. This market study considers a market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. All the data and statistics provided in this Pharma Clinical Trial Digitization Market report are backed up by latest and proven tools and techniques such as SWOT analysis and Porter's Five Forces Analysis.

Pharma clinical trial digitizationmarket is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 5.7% in the above-mentioned forecast period. Growing demand for personalized medicine is expected to create new opportunity for the pharma clinical trial digitization market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market

According to this report Global Pharma Clinical Trial Digitization Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Pharma Clinical Trial Digitization Market includes comprehensive information derived from depth study on Pharma Clinical Trial Digitization Industry historical and forecast market data. Global Pharma Clinical Trial Digitization Market Size to Expand moderately as the new developments in Pharma Clinical Trial Digitization and Impact of COVID19 over the forecast period 2020 to 2027.

In the Pharma Clinical Trial Digitization Market report, market drivers and market restraints are studied carefully along with the analysis of the market structure. This market research report is an ideal guide to attain information or key data about market, emerging trends, product usage, motivating factors for customers, competitor strategies, brand positioning, customer preferences, and customer behaviour. While generating this Pharma Clinical Trial Digitization Market research report, customer satisfaction is kept on the utmost priority. To thrive in this competitive market place, market research report plays a vital role which gives important and meaningful market insights for the business.

TO UNDERSTAND HOW COVID-19 IMPACT AND POST OPPORTUNITIES IS COVERED IN THIS REPORT GET FREE COVID-19 SAMPLE @ https://www.databridgemarketresearch.com/covid-19-impact/global-pharma-clinical-trial-digitization-market

Top key players covered in the pharma clinical trial digitization market report are:

Access Full Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-pharma-clinical-trial-digitization-market

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

How Does This Market Insights Help?

Pharma Clinical Trial Digitization Market share (regional, product, application, end-user) both in terms of volume and revenue along with CAGR

Key parameters which are driving this market and restraining its growth

What all challenges manufacturers will face as well as new opportunities and threats faced by them

Learn about the market strategies that are being adopted by your competitors and leading organizations

To gain insightful analyses of the market and have a comprehensive understanding of the Pharma Clinical Trial Digitization Market and its commercial landscape

Key Pointers Covered in the Pharma Clinical Trial Digitization Market Industry Trends and Forecast to 2027

Pharma Clinical Trial Digitization Market Scope

The pharma clinical trial digitization market is segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of pharma clinical trial digitization market is further analyzed based on maximum granularity into further segmentation. On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing. Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment. The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial IT systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Visit to full Report @ https://www.databridgemarketresearch.com/reports/global-pharma-clinical-trial-digitization-market

Competitive Landscape

Pharma clinical trial digitization market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to pharma clinical trial digitization market.

For More Information or Query or Customization Before Buying Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharma-clinical-trial-digitization-market

Table of Contents: Global Pharma Clinical Trial Digitization Market

Get Complete Details with TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market

See The Complete Table of Contents and List of Exhibits, As Well as Selected Illustrations and Example Pages from This Report.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Trending Related Reports:

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:corporatesales@databridgemarketresearch.com

Read more here:
Pharma Clinical Trial Digitization Market: 2020 Global Segment Analysis (Services, Application, Themes, Country), Future Trend Rising at +5.70% CAGR...

MOH approves Cocoon Platform to manufacture a CD19 CAR-T cell immunotherapy for Phase II clinical trial for B-cell malignancies.

Contract Pharma Staff09.09.20

Lonza and Sheba Medical Center announced the first patient has been treated at Sheba Medical Center with a CD19 CAR-T cell immunotherapy manufactured using Lonzas Cocoon Platform. The Cocoon Platform is an automated and functionally closed system for patient-scale cell therapy manufacturing, designed to overcome some of the manufacturing challenges of manually producing personalized medicines, including autologous CAR-T cell therapies.

Sheba Medical Center and Lonza have collaborated to translate Shebas open, manual manufacturing process into the Cocoon Platform since mid-2019. Teams from Lonza Personalized Medicine and Collaborative Innovation Center (CIC) in Haifa, IL worked closely with Sheba Medical Center to complete process development, tech transfer, training and a full clinical comparability study requiring regulatory approval before the first patient could be treated. The approval of the Cocoon Platform clinical comparability study illustrates the platforms flexibility and ability to manufacture a final cell immunotherapy which is comparable to the original manual process while meeting the extensive patient safety criteria.

Sheba and Lonza plan to treat additional patients under the same CD19 CAR-T cell immunotherapy protocol using the Cocoon Platform. The Cocoon Platform will enable Sheba to reduce immunotherapy manufacturing costs by lowering manpower, time, and space requirements. The goal is to ultimately allow Sheba to deliver potentially curative cellular immunotherapies to more patients.

See the article here:
CD19 CAR-T Therapy Manufactured Using Lonza's Cocoon Platform - Contract Pharma

New York, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Wearable Electronics Industry" - https://www.reportlinker.com/p03180729/?utm_source=GNW After smartphones and tablets, smart wearables is the new innovation taking the technology to a fevered pitch in the consumer electronics industry. These tiny devices hold the potential to replace smartphones, make the many benefits of digital health real and achievable, enable the rise of hyper-connected interactive enterprises, and make clothing smart, fashionable, functional and comfortable. Benefits of wearables devices include lightweight, extreme portability, durable, easily transportable, convenience, ease-of-use and comfort. Smartwatch is the most popular form and dominant factor for wearables. Other evolving new designs include smart glasses, goggles, bracelets, armbands, necklaces, lanyards, pins, clips, headbands, headsets, belts, shoes, shirts, Jackets and pants, among others. The biggest area of impact in electronic wearables is in the healthcare industry. Medical grade wearables are poised to create a revolution in personalized digital healthcare. Wearables will enable telehealth via remote patient monitoring (RPM) capabilities making healthcare services more efficient, self-determined and cost efficient. Opportunities in this space are immense as the current healthcare system seeks to utilize telehealth to advance value based care goals. A key benefit of telehealth is its ability to drive positive patient experience and eliminate access barriers to offer patient-centric and convenient care. Wearables will also play a key role in precision medicine by providing physicians better knowledge of patients health. Integration of sensors such as physiological sensors and biochemical sensors will provide continuous monitoring of a patients vital signs and timely clinical decisions can be taken such as therapy modifications based on subtle changes observed in health patterns.

From simple biophysical/ biochemical monitoring (BP & diabetes), continuous innovation will expand applications to more advanced continuous arrhythmia detection and monitoring blood pulse signals from human femoral, carotid and radial arteries. Another exciting area of innovation is the integration of artificial intelligence (AI) enabled Healthbot applications in smartwatches designed to help patients with disease/therapy management and counselling. Healthbots have the potential to expand the outreach of healthcare services especially in countries and regions where doctor to patient ratio is low thus creating a bottleneck in accessing primary care services. In the addition to healthcare, clothing also represents and emerging area of opportunity for wearables. Innovative development of flexible, transparent graphene electrodes and their integration into commonly used textile fibers will be the first step forward in revolutionizing e-textiles. Significant R&D resources are therefore being sunk into developing processes and engineering techniques to integrate graphene in textiles as it hold the key that will unlock a new universe of commercial application opportunities in the coming years. The United States and Europe represent large markets worldwide with a combined share of 67.9% of the market. China ranks as the fastest growing market with a CAGR of 28.4% over the analysis period supported by the fact that the country leads the world in digital health adoption.

Read the full report: https://www.reportlinker.com/p03180729/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Wearable Technology: The Transition from Science Fiction to Reality Historical Journey of Wearable Technology Applications & Solutions of Wearable Electronics Wearable Electronics Market: Expanding Applications of Miniaturized, High Performance Wearable Devices Boosts Prospects Wrist-Wear Dominates Global Wearable Electronics Market Consumer Electronics: The Largest End-Use Market Developed Regions Lead, Developing Regions at the Forefront of Future Growth Global Competitor Market Shares Wearable Electronics Competitor Market Share Scenario Worldwide (in %): 2019 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS Apple, Inc. (USA) Bose Corporation (USA) Epson America, Inc. (USA) Fitbit, Inc. (USA) Garmin Ltd. (USA) Huawei Technologies Co., Ltd. (China) Infineon Technologies AG (Germany) LG Electronics, Inc. (South Korea) Lifesense Group B.V. (The Netherlands) Lumus Ltd. (Israel) Misfit, Inc. (USA) Qualcomm Technologies, Inc. (USA) ReSound (Denmark) Samsung Electronics Co., Ltd. (South Korea) Shimmer Research, Inc. (Ireland) Sony Corporation (Japan) Texas Instruments, Inc. (USA) Titan Industries Ltd. (India) Vuzix Corporation (USA) Xiaomi Corporation (China)

3. MARKET TRENDS & DRIVERS Expanding Internet Connectivity and Growing Consumer Demand for Advanced Wearable Devices Fuels Market Prospects Rapid Increase in Penetration Rate of Internet: 2018 Vs. 2009 Rising Number of IoT and Connected Devices Drive Growth in Wearable Electronics Market World IoT Market: Number of Connected Devices (in Million) for Years 2016, 2018E, 2020P and 2022P Market Share Scenario of Connected Devices in Global Internet of Things (IoT) by Geographic Region: 2019 & 2024 Growing Prominence of Wearable Tech in Healthcare Propels Market Growth Global Digital Healthcare Opportunity (in US$ Billion) for the Years 2017, 2019, 2022, 2024 and 2026 Chronic Diseases Management: A Key Focus Area Need for Continuous Monitoring of Elderly Patients as Part of Chronic Disease Management Drives Growth: Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 Rising Consumer Awareness about Health & Fitness Spells Growth for Wearables Potential Role for Wearable Electronics in Patient Monitoring and Tracking Systems Smart Clothing Gains Acceptance in Neonatal Monitoring Wearables Technology Makes Diabetes Manageable Rising Diabetes Prevalence Presents Opportunity for Wearable Electronics Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2019 and 2045 ECG Monitoring Wearables: A Promising Area of Growth Increasing Significance of Wearables in Pain Management Wearable Sleep Monitoring Technology Wearable EEG Monitors Smart Medical Textile Garments: An Emerging Area of Interest Wrist Wear: A Revolutionary Wearable Phenomenon Fuels Growth Hybrid Smartwatch Sales Drive Market Growth Smart Glasses for Multiple Industry Applications With Wearable Computing Gaining Mainstream Attention, the Time is Ripe for Mobility in the Realm of Augmented Reality Growing Technology & Commercialization Activity Surrounding AR to Benefit Development of Smart AR Glasses: Global Market for Augmented Reality Hardware, Software & Applications (in US$ Million) for the Years 2015, 2018 & 2022 Global % Share Breakdown of Wearable AR Devices in the Market by Form Factor (2019) Activity Trackers to Lead Growth in Wearable Sports and Fitness Devices Market A Comparative Review of Popular Fitness Trackers Increasing Obesity Levels Underpin Market Growth Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 Smart Clothing Transforming the Wearable Technology Products Market Smart Fabrics: The Next Big Wave of Wearables Novel Opportunities for Smart Fabrics across Various Sectors Healthcare Transportation Sports & Fitness Workwear Microencapsulation & Nanotechnologies: Harbingers of Future Growth Hearables, the Smart Headphones, Come to the Fore Increasing Popularity of Wearables in Infotainment & Gaming Industry Enterprise Applications of Wearables Present Growth Potential for Wearable Electronics Market Wearable Technology Boosts CRM Rising Adoption of Wearable Technology in Industrial Sector Drives Growth Cloud Computing Drives the Momentum in Wearable Electronics Market Combination of AI and Wearable Technology Transforms the Wearable Electronics Market Global Market for Wearable AI in US$ Billion for the Years 2018, 2020, 2022 and 2024 Development of Low Power Electronics: An Opportunity for Wearable Electronics Market Ultra-low Power Microcontrollers Extend Battery Life of High- Performing, New Generation Wearable Devices: Global Ultra-low Power Microcontroller Market (In US$ Billion) for the Years 2018, 2020, 2022 & 2025 A Peek into Enabling Technologies Technical Aspects of Wearable Devices Sensor Integration for Advanced Wearable Technology Battery Power: An Important Criterion for Success Technology Advancements Power Wearable Electronics Market Collaboration Vital for Innovations in Wearable Tech Key Challenges Confronting Wearable Electronics Market Common Issues with Wearable Electronics Wearables Attract Venture Capital Funding

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Wearable Electronics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 2: World 7-Year Perspective for Wearable Electronics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Wristwear by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 4: World 7-Year Perspective for Wristwear by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 5: World Current & Future Analysis for Eyewear by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 6: World 7-Year Perspective for Eyewear by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 7: World Current & Future Analysis for Hearables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 8: World 7-Year Perspective for Hearables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Bodywear by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 10: World 7-Year Perspective for Bodywear by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 12: World 7-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 13: World Current & Future Analysis for Memory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 14: World 7-Year Perspective for Memory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 15: World Current & Future Analysis for Sensor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 16: World 7-Year Perspective for Sensor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 17: World Current & Future Analysis for Display by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 18: World 7-Year Perspective for Display by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 19: World Current & Future Analysis for Connectivity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World 7-Year Perspective for Connectivity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 21: World Current & Future Analysis for PCBs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 22: World 7-Year Perspective for PCBs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 23: World Current & Future Analysis for Other Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 24: World 7-Year Perspective for Other Components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 25: World Current & Future Analysis for Consumer Electronics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 26: World 7-Year Perspective for Consumer Electronics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 27: World Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 28: World 7-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 29: World Current & Future Analysis for Enterprise & Industrial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 30: World 7-Year Perspective for Enterprise & Industrial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

Table 31: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 32: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Wearable Electronics Market in the US: An Overview Penetration of Wearables among Adults in the US: Adult Wearable Users as % of Population Americans Rise Up to ?Quantified Self? Evolving Healthcare in the US to Drive Demand for Wireless Devices Wearable Devices to Mitigate Medical Concerns of Elderly Individuals US Population Breakdown by Age Group (in %) for 2019 Table 33: USA Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 34: USA 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 35: USA Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 36: USA 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 37: USA Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 38: USA 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

CANADA Table 39: Canada Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 40: Canada 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 41: Canada Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 42: Canada 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 43: Canada Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 44: Canada 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

JAPAN Table 45: Japan Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 46: Japan 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 47: Japan Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 48: Japan 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 49: Japan Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 50: Japan 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

CHINA Wearable Technology Adoption on the Rise in China Chinese Wearable Electronics Market Share Analysis (in %): 2019 Table 51: China Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 52: China 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 53: China Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 54: China 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 55: China Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 56: China 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

EUROPE Market Facts & Figures European Wearable Electronics Market: Competitor Market Share Scenario (in %) for 2019 Market Analytics Table 57: Europe Current & Future Analysis for Wearable Electronics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027

Table 58: Europe 7-Year Perspective for Wearable Electronics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

Table 59: Europe Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 60: Europe 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 61: Europe Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 62: Europe 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 63: Europe Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 64: Europe 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

FRANCE Table 65: France Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 66: France 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 67: France Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 68: France 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 69: France Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 70: France 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

GERMANY Table 71: Germany Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 72: Germany 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 73: Germany Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 74: Germany 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 75: Germany Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 76: Germany 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

ITALY Table 77: Italy Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 78: Italy 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 79: Italy Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 80: Italy 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 81: Italy Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 82: Italy 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

UNITED KINGDOM Table 83: UK Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 84: UK 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Table 85: UK Current & Future Analysis for Wearable Electronics by Component - Memory, Sensor, Display, Connectivity, PCBs and Other Components - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 86: UK 7-Year Perspective for Wearable Electronics by Component - Percentage Breakdown of Value Sales for Memory, Sensor, Display, Connectivity, PCBs and Other Components for the Years 2020 & 2027

Table 87: UK Current & Future Analysis for Wearable Electronics by Application - Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 88: UK 7-Year Perspective for Wearable Electronics by Application - Percentage Breakdown of Value Sales for Consumer Electronics, Healthcare, Enterprise & Industrial and Other Applications for the Years 2020 & 2027

REST OF EUROPE Table 89: Rest of Europe Current & Future Analysis for Wearable Electronics by Product - Wristwear, Eyewear, Hearables, Bodywear and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027

Table 90: Rest of Europe 7-Year Perspective for Wearable Electronics by Product - Percentage Breakdown of Value Sales for Wristwear, Eyewear, Hearables, Bodywear and Other Products for the Years 2020 & 2027

Read this article:
The global market for Wearable Electronics is projected to reach US$61.4 billion by 2025 - GlobeNewswire

Yes, even your metabolism has a memory and it can hold a grudge for years. In people with diabetes, periods of high blood sugar can negatively impact their health years later, even if they get their blood sugar under control. While this metabolic memory phenomenon has been known for years, why it happens is poorly understood.

Rama Natarajan, Ph.D., Professor and Chair of the Department of Diabetes Complications & Metabolism at City of Hope, turned to our epigenome for the answer.

Weve shown the first link between DNA methylation in blood and stems cells, blood sugar history, and future development of complications, said Natarajan. This highlights the importance of good glycemic control to prevent long-term complications.

The history of metabolic memory

We now know high blood sugar can lead to a variety of complications, including eye disease, kidney disease, nerve problems, heart disease, and stroke. But the relationship between strict blood sugar control and complication risk wasnt well understood before the 1980s.

Back in 1983, the Diabetes Control and Complications Trial (DCCT) began tracking complications in 1,441 participants with type 1 diabetes. Researchers compared the occurrence of long-term complications between participants who tightly regulated their blood glucose levels to those who followed less strict standard regulation.

After 10 years, the difference was striking the risk of diabetic complications was reduced in participants who tightly regulated their blood sugar but not in those following standard regulation. In other words, a person with higher blood sugar had a higher risk of complications.

To continue following the DCCT patients, the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up trial began at the end of DCCT in 1993 and is ongoing. At the end of DCCT, all participants were encouraged to adopt strict blood sugar regulation; many in the standard regulation group did.

Despite blood sugar regulation being very similar in all the patients (as measured by hemoglobin A1c, called HbA1c), differences persisted between the two original intervention groups. The phenomenon of long-term effects from high or variable blood sugar control is called metabolic memory (or the legacy effect in type 2 diabetes).

Complications resulted from total high blood sugar exposure it didnt matter whether the person was exposed to slightly elevated levels over a long time or high levels over a short time.

So, what caused the sweet sugar molecule to become so destructive?

Sugary destruction

Extra sugar in your blood can interact with your cells, DNA, and proteins, adding itself onto things it shouldnt be on through a process called glycation. In fact, HbA1c can be thought of as sugar-coated red blood cells.

The sugar-coated molecules cant function as well, if at all, and the damage begins a self-perpetuating cycle. Not only do these damaged molecules stop working, they can also accumulate in the skin, eyes, and other organs, causing damage. Build-up of sugar-coated molecules can trigger the creation of harmful free radicals, causing oxidative stress and feeding a destructive cycle.

Although sugar can directly modify molecules, it can also trigger other epigenetic modifications. These modifications can control how genes are expressed, changing protein levels in cells.

There hasnt been a strong genetic association with diabetic complications very few genetic mutations have been strongly linked to complications, Natarajan explained. But we knew the epigenome is what makes identical twins different and can have implications into why one gets diabetes or cancer and the other doesnt. So, we turned our focus to epigenetics.

Epigenetics and diabetes

Natarajan sought to explain the long-term sugary destruction wrought by high blood sugar by searching the epigenome. Her lab specifically looks for one type of modification called DNA methylation, where a tiny molecule called a methyl group is added onto DNA.

Epigenetics is the coating on top of genetics that can be altered by environmental influences, Natarajan said. We started focusing on the role of epigenetics in developing diabetes and its complications because we know that lifestyles, improper diet, lack of exercise, and even viruses can affect epigenetics.

Natarajans lab began collaborating with the DCCT trial group, analyzing data collected through the trial for epigenetic clues to explain the metabolic memory of complications. They found more modifications associated with active genes on proteins called histones that are wrapped by DNA in participants with regular blood sugar control compared to the strict controllers. Even more interesting was that many epigenetic DNA methylation variations between the two groups persisted through at least 17 years of follow-up in the EDIC study.

These changes were in important genes related to complications, showing something about persistent epigenetic programming in peripheral blood cells, commented Natarajan. Previous high blood sugar episodes could be a key factor in why these genes were continually misbehaving.

Now, Natarajans lab illuminated even more links between epigenetic changes, blood sugar history, and metabolic memory in their recent Nature Metabolism paper. Persistent epigenetic modifications of a few key genes were detected in participants with previously less regulated blood sugar who developed either retinopathy or nephropathy. They showed that DNA methylation is a key link between a patients HbA1c history, metabolic memory, and development of future complications.

Many HbA1c-associated modifications were in stem cells and the blood cells they create. Even though blood cells are turned over relatively quickly, stem cells stick around for a long-time, so changes in stem cells can have long-term consequences.

The important thing we found was the connection to stem cells, explained Natarajan. Were asking how these changes alter inflammatory gene expression and how we can interrupt those pathways.

Sugar-modified genes arent so sweet

Natarajans lab sorted through all the modified genes to find the most common modifications in participants with less strict blood sugar control. The most commonly modified gene coded for thioredoxin-interacting protein (TxNIP).

TxNIP is not a new protein, but the discovery that its DNA methylation is altered by different glycemic control is new, Natarajan added.

Thioredoxin-interacting protein is known to be highly regulated in certain pancreas cells, called beta cells, that release insulin. The plot thickened when high blood sugar was found to increase TxNIP protein production. Even more interesting, high TxNIP protein levels make beta-cells dysfunctional, ultimately leading to their untimely death. So, high blood sugar triggers more TxNIP to be produced, possibly through epigenetic modifications of the TxNIP gene, which ultimately leads to the death of insulin-producing beta cells.

Showing that the TxNIP gene can be epigenetically modified for years and years suggests that it could be one of the culprits causing long-term problems in diabetes, Natarajan said.

The proteins that TxNIP interacts with, called thioredoxins, protect against oxidative stress. TxNIP can bind to and inactivate thioredoxin to increase oxidative stress by increasing reactive oxygen species (ROS). In mouse cells in a dish, high glucose exposure triggered increased ROS levels mediated by TxNIP, leading to oxidative stress. Oxidative stress can trigger cell and organ damage, so this could be one mechanism explaining diabetes-induced damage.

Her lab also found epigenetic changes in other genes related to inflammation and inflammation-related processes.

Next steps and clinical implications

Natarajans lab is continuing to study the link between blood sugar history, epigenetics, and other complications of diabetes. They are also expanding their scope, searching the entire genome for more epigenetic modifications linked with past blood sugar maintenance.

This study also lays the groundwork for further studies with meaningful clinical implications, including developing epigenetic biomarkers for diabetic complications. In the future, Natarajan says a simple blood test looking at key epigenetic modifications, along with HbA1c history, could be used to predict future risk of retinopathy, nephropathy, and neuropathy. This would allow the doctor to figure out who should have early and more aggressive treatment to mitigate complication risk.

While these studies were done in type 1 diabetes patients, other studies in type 2 diabetes patients have shown similar epigenetic modifications after history of higher blood sugar levels.

Turning knowledge into potential drugs

What about doing something about the epigenetic modifications can we remove them? As a matter of fact, yes!

There is an interesting new type of experimental drug on the horizon called epigenetic editing. The hot new technology CRISPR isnt just for cutting out chunks of DNA or controlling genes it can also be used to insert or remove epigenetic modifications. While this technology is still experimental and in early preclinical animal studies, the potential is very exciting.

A CRISPR/enzyme pair can be used the CRISPR genetic material can hunt down the genetic spot you want to change; and the attached enzyme can snip or add certain molecules to the DNA, effectively removing or creating an epigenetic modification, thereby activating or silencing the targeted gene.

Enzymes such as methyltransferase or demethylase can add or remove methyl groups from genes. Because they just change what is on the gene or histone wrapped around it (not the genetic sequence itself), the gene itself isnt tampered with, meaning there could be less genetic complications associated with CRISPR epigenetic editing.

This is a futuristic thing, Natarajan concluded. The combination of genetics and epigenetics is going to be the future of personalized medicine.

Original post:
Can High Blood Sugar Haunt People with Diabetes Even After it is Under Control? - BioSpace

DUBLIN--(BUSINESS WIRE)--The "Global Digital PCR (d-PCR) Market: Focus on Product-Type, Application, End User, Region, and Competitive Landscape - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The publisher's healthcare experts have found digital PCR (d-PCR) market to be one of the most rapidly evolving markets and the global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025. The market is driven by certain factors, which include the rising incidence of infectious disease, such as recent pandemic COVID-19, inciting the development of high-throughput diagnostics, increasing adoption of personalized medicine for the screening and diagnostics of genetic disorders, and significant external funding for executing R&D exercises.

The market is favored by the development of digital PCR-based solutions for early diagnosis and rare mutation detection with absolute quantification of the target sample. The gradual increase in the prevalence of infectious disease due to pandemic COVID-19 globally has furthered the digital PCR (d-PCR) market.

Furthermore, several diagnostic companies are focusing on the development of digital PCR diagnostics with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes.

Within the research report, the market is segmented on the basis of product type, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Market Report Coverage - Digital PCR (d-PCR)

Market Segmentation

Regional Segmentation

Key Questions Answered in this Report:

Market Dynamics

Drivers

Restraints

Opportunities

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/c5wtke

Read more:
Global Digital PCR Market (2020 to 2025) - Focus on Product-type, Application, End-user, Region, and Competitive Landscape - ResearchAndMarkets.com -...

CAMBRIDGE, Mass., Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.The approval is based on data from the Phase 1/2 ARROW clinical trial, which showed efficacy for GAVRETO in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement. Under Blueprint Medicines' collaboration with Roche, Blueprint Medicines and Genentech, a member of the Roche Group, will co-commercialize GAVRETO in the U.S.

GAVRETO is a once-daily oral RET-targeted therapy developed by Blueprint Medicines. It is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately 1 to 2 percent of patients with NSCLC.Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy.

"Targeted therapies have dramatically improved care for patients with non-small cell lung cancer driven by oncogenes, including EGFR and ALK, and the approval of the selective RET inhibitor pralsetinib, or GAVRETO, marks another milestone in a paradigm shift toward precision medicine," said Vivek Subbiah, M.D., associate professor of Investigational Cancer Therapeutics and center medical director of the Clinical Center for Targeted Therapy at The University of Texas MD Anderson Cancer Center, and an investigator on the ARROW trial. "Patients treated with GAVRETO had durable clinical responses, with a subset achieving complete responses characterized by the resolution of all target lesions, an uncommon outcome in metastatic lung cancer. We observed this activity with or without prior therapy and regardless of RET fusion partner or the presence of brain metastases. This approval represents an important advance with the potential to change standards of care for patients with RET fusion-positive non-small cell lung cancer, who have historically had limited treatment options."

"GAVRETO is the second breakthrough therapy discovered by Blueprint Medicines that has received FDA approval in 2020, less than 10 years since the company started operations. This progress reflects the power of our scientific platform, our focus on delivering transformative outcomes to patients and our urgency to address important medical needs," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "We are working with our partner Genentech to rapidly bring GAVRETO to healthcare providers and patients in the U.S., applying our complementary capabilities to support patient identification and access to treatment. Ultimately, we aim to accelerate the identification of patients with RET fusion-positive non-small cell lung cancer and enable them to rapidly access treatment with GAVRETO."

GAVRETO was granted accelerated approval by the FDA1, and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. In 87 patients previously treated with platinum-based chemotherapy, the overall response rate (ORR) was 57 percent (95% CI: 46%, 68%) with a 5.7 percent complete response (CR) rate, and the median duration of response (DOR) was not estimable (95% CI: 15.2 months, not estimable). In 27 treatment-nave patients who were ineligible for platinum-based chemotherapy per the study protocol, the ORR was 70 percent (95% CI: 50%, 86%) with an 11 percent CR rate, and the median DOR was 9.0 months (95% CI: 6.3 months, not estimable). GAVRETO has warnings and precautions of interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, risk of impaired wound healing and risk of embryo-fetal toxicity.

"We applaud therapeutic advancements like GAVRETO that allow lung cancer treatment to be personalized based on the molecular drivers in a person's tumor," said Andrea Ferris, President and CEO of LUNGevity. "There are now a number of tumor-specific gene alterations that can be targeted with FDA-approved therapies, reflecting an important inflection point supporting the widespread use of comprehensive biomarker testing. At LUNGevity, we want to empower patients and their families to discuss biomarker testing with clinicians prior to initiating treatment."

Biomarker testing for RET is the only way to identify patients with metastatic NSCLC who are candidates for treatment with GAVRETO. RET fusions can be identified with available biomarker tests, including next-generation sequencing with tumor tissue or liquid biopsies. In the ARROW trial, RET fusions were detected using next-generation sequencing, FISH or other methods.

Blueprint Medicines and Genentech plan to make GAVRETO available in the U.S. within one week. GAVRETO will be available in a 100 mg dose strength, and the recommended starting dose is 400 mg once daily.

Blueprint Medicines isdedicated to helping patients access treatment with GAVRETO and delivering support throughout their treatment journey. As part of this commitment,Blueprint Medicines is providing YourBlueprint, a patient support program that offers access and affordability solutions for individuals receiving GAVRETO. For more information, visitYourBlueprint.comor call 1-888-BLUPRNT (1-888-258-7768), Monday to Friday,8:00 a.m. to 8:00 p.m. ET. Healthcare providers who prescribe GAVRETO can fill out an enrollment form at YourBlueprint.com/HCPto help patients access thesupport services.

GAVRETO is a cornerstone precision medicine for Blueprint Medicines, supporting its commitment to advance targeted therapies for patients with NSCLC. As previously announced in November 2019, Blueprint Medicines is pursuing two research programs targeting well-characterized resistance mutations in patients with EGFR-driven NSCLC.

New Drug Application Accepted by FDA for the Treatment of RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer

Blueprint Medicines today announced the FDA has accepted the company's new drug application (NDA) for pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. This NDA was accepted for review under the FDA's Real-Time Oncology Review (RTOR) pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. The FDA granted priority review and set an action date of February 28, 2021 under the Prescription Drug User Fee Act.

Conference Call Information

Blueprint Medicines will host a live webcast on Tuesday, September 8, 2020 beginning at 8:00 a.m. ET to discuss the FDA approval of GAVRETO. To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 6266646. A webcast of the conference call will be available under "Events and Presentations" in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 90 days following the call.

About GAVRETO (pralsetinib)

GAVRETO (pralsetinib) is a once-daily oral targeted therapy approved by the FDA for the treatment of adults with metastatic RET fusion-positive NSCLC as detected by an FDA approved test.It is designed to selectively and potently target oncogenic RET alterations. In pre-clinical studies, GAVRETO inhibited RET at lower concentrations than other pharmacologically relevant kinases, including VEGFR2, FGFR2 and JAK2.For more information, visit GAVRETO.com.

GAVRETO is not approved for the treatment of any other indication in the U.S. by the FDA or for any indication in any other jurisdiction by any other health authority.

Blueprint Medicines and Roche are co-developing pralsetinib globally (excluding Greater China) for the treatment of patients with RET-altered NSCLC, various types of thyroid cancer and other solid tumors. The FDA has accepted an NDA for pralsetinib for the treatment of RET-mutant MTC and RET fusion-positive thyroid cancer, and the European Medicines Agency has validated a marketing authorization application for pralsetinib for the treatment of RET fusion-positive NSCLC. The FDA has granted breakthrough therapy designation to pralsetinib for the treatment of RET fusion-positive NSCLC that has progressed following platinum-based chemotherapy and for RET mutation-positive MTC that requires systemic treatment and for which there are no acceptable alternative treatments.

Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of pralsetinib in Greater China, which encompasses Mainland China, Hong Kong, Macau and Taiwan.

Enrollment is ongoing in the Phase 1/2 ARROW trial, including for patients with various RET fusion-positive solid tumors, and the Phase 3 AcceleRET Lung trial for treatment-nave patients with RET fusion-positive NSCLC. For more information about pralsetinib clinical trials, visit http://www.clinicaltrials.gov or http://www.blueprintclinicaltrials.com.

About RET-Altered Solid Tumors

RET activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and multiple types of thyroid cancer. RET fusions are implicated in approximately 1 to 2 percent of patients with NSCLC and approximately 10 to 20 percent of patients with papillary thyroid cancer, while RET mutations are implicated in approximately 90 percent of patients with advanced MTC. In addition, oncogenic RET fusions are observed at low frequencies in colorectal, breast, pancreatic and other cancers, as well as in patients with treatment-resistant EGFR-mutant NSCLC.

Important Safety Information

Pneumonitisoccurred in 10% of patients who received GAVRETO, including 2.7% with Grade 3/4, and 0.5% with fatal reactions. Monitor for pulmonary symptoms indicative of interstitial lung disease (ILD)/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD.

Hypertensionoccurred in 29% of patients, including Grade 3 hypertension in 14% of patients. Overall, 7% had their dose interrupted and 3.2% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue GAVRETO based on the severity.

Hepatotoxicity: Serious hepatic adverse reactions occurred in 2.1% of patients treated with GAVRETO. Increased AST occurred in 69% of patients, including Grade 3/4 in 5.4% and increased ALT occurred in 46% of patients, including Grade 3/4 in 6%. The median time to first onset for increased AST was 15 days (range: 5 days to 1.5 years) and increased ALT was 22 days (range: 7 days to 1.7 years). Monitor AST and ALT prior to initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on severity.

Grade 3 hemorrhagic events occurred in 2.5% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event. Permanently discontinue GAVRETO in patients with severe or life-threatening hemorrhage.

Impaired wound healingcan occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, GAVRETO has the potential to adversely affect wound healing. Withhold GAVRETO for at least 5 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution of wound healing complications has not been established.

Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the final dose. Advise women not to breastfeed during treatment with GAVRETO and for 1 week after the final dose.

Common adverse reactions (25%)were fatigue, constipation, musculoskeletal pain, and hypertension. Common Grade 3-4 laboratory abnormalities (2%) were decreased lymphocytes, decreased neutrophils, decreased phosphate, decreased hemoglobin, decreased sodium, decreased calcium (corrected) and increased alanine aminotransferase (ALT).

Avoid coadministration with strong CYP3A inhibitors. Avoid coadministration of GAVRETO with combined P-gp and strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the GAVRETO dose. Avoid coadministration of GAVRETO with strong CYP3A inducers. If coadministration cannot be avoided, increase the GAVRETO dose.

Please click here to see the full Prescribing Information for GAVRETO.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two FDA-approved precision therapies and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit http://www.BlueprintMedicines.comand follow us onTwitter(@BlueprintMeds) andLinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' views with respect to the approval of GAVRETO and the implications of such approval for patients, caregivers and healthcare professionals; expectations regarding the ability to accelerate the identification of patients with RET fusion-positive NSCLC; expectations regarding when GAVRETO will be commercially available in the U.S. and patients' ability to rapidly access treatment with GAVRETO; Blueprint Medicines' plans and ability to provide robust support services for patients prescribed GAVRETO through YourBlueprint; plans for Blueprint Medicines and Roche to expand development of pralsetinib in additional treatment settings; plans, timelines and expectations for interactions with the FDA and other regulatory authorities, including for the separate NDA for pralsetinib for the treatment of patients with RET-mutant MTC and RET fusion-positive thyroid cancer; the potential benefits of Blueprint Medicines' current and future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines' ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines' ability and plans in establishing a commercial infrastructure, and successfully launching, marketing and selling current or future approved products, including AYVAKIT (avapritinib) and GAVRETO; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT and GAVRETO or obtain marketing approval for AYVAKIT and GAVRETO in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to develop and commercialize companion diagnostic tests for its current and future drug candidates; and the success of Blueprint Medicines' current and future collaborations, partnerships or licensing arrangements, including Blueprint Medicines' global collaboration with Roche for the development and commercialization of pralsetinib. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Reference

1GAVRETO (pralsetinib) Prescribing Information (U.S.).Blueprint Medicines Corporation,Cambridge, Massachusetts, USA;September 2020.

Trademarks

Blueprint Medicines, AYVAKIT, GAVRETO, YourBlueprint and associated logos are trademarks of Blueprint Medicines Corporation.

View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-ret-fusion-positive-non-small-cell-lung-cancer-301124707.html

SOURCE Blueprint Medicines Corporation

Excerpt from:
Blueprint Medicines Announces FDA Approval of GAVRETO (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell...

Organoid cell culture has transformed cell-based assays in drug discovery and basic biology by conferring physiologic relevance to in vitro cell-based biological models. When provided with a suitable growth environment, including appropriate cultureware, growth factors, extracellular matrix, nutrients, and culture media, organ-derived progenitor cells harvested from patients grow and assemble into three-dimensional structures organoids which incorporate all cell types normally found in the original tissue, and allow physical and chemical interactions between and among cells. By providing greater physiologic relevance and a species- or patient-specific test platform, organoids overcome many limitations of conventional 2D cultures and even live-animal disease models.Organoids arise from organ-derived adult pluripotent stem cells, organ stem cells, or cancer stem cells which possess the innate capacity to expand and differentiate into multiple cell types. Organoids generated from dozens of tissues and organs available commercially, or accessible through published protocols include patient-derived models of liver, heart, pancreas, brain, GI tract, kidney, and recently, of human airwayssuitable for drug and vaccine development and for studying infectious human respiratory diseases.

Corning Life Sciences has collaborated with HUB since 2014 to provide advanced organoids and related technology.

Dr Clevers technology allowed, for the first time, the expansion of adult stem cell-derived organoids in genetically stable form and ultimately, the generation of in vitro models of any epithelial disease from any patient.

A second key benefit was indefinite expansion similar to that of transformed cells, but without the genetic abnormalities inherent in cancer cells. Previously, organoids were generated from embryonic or induced pluripotent stem cells, or from tumor cells which by necessity are genetically modified and therefore unrepresentative of the patient.

Under HUBs commercial development, organoid technology also provides standardization and consistency which is difficult to match, especially with primary cell cultures. Biopsies from the same patient collect differing quantities of cells at widely varying stages of cell lifecycle. When cultured under identical HUB protocols adult progenitor cells give rise to organoids with exactly the same cells in the same proportions, physical configuration, and genetics, every time, and with broad expansion capabilities.

Similarly, transformed cells grown on plastic have modified their gene expression to adapt to tissue culture conditions. Studies with such cells can be useful, provided investigators recognize that the patients original genetics have not been preserved. In HUB organoids the patients molecular footprint is maintained.

One field where this has been particularly useful is infectious diseases. Viruses have evolved to infect and replicate in cells in their normal physiological states. For example, respiratory syncytial virus (RSV) readily grows in organoids but will not infect transformed cells because the cells lack the relevant receptors.

Cell-based studies of airway diseases topical in light of the current COVID-19 pandemic were hampered for years for this reason, and technology for expanding primary cell cultures sufficiently for large-scale studies did not exist. By preserving critical cell surface receptors for infectious agents, the HUB method allows the study of such pathogens as RSV, human papillomavirus, norovirus, coronavirus, influenza, malaria and many others.

Epithelial cells are the first point of contact for pathogenic microbes in the respiratory tract, and fortuitously the cell types most easily grown as organoids. Receptors on airway epithelia and alveolar cells sense infection, which initiates mucosal barrier immunity through club, ciliated, basal, goblet and neuroendocrine cells, which together clear inhaled pathogens.

In a recent Science paper, researchers from the Hubrecht Institute and Erasmus Medical Center reported on how gut organoids helped them to uncover two potential avenues for treating or preventing infection with SARS-CoV-2, the coronavirus responsible for the current pandemic. SARS-CoV-2 is known to infect the lungs, but clinical evidence suggests intestinal involvement in both symptomatology and transmission. For example, rectal swabs contain viral RNA for a time after nasal swabs indicate the infection has resolved, suggesting gastro-intestinal infection and possibly fecaloral transmission.

Differentiated enterocytes strongly express the SARS-CoV-2 angiotensin converting enzyme 2 (ACE2) receptor through which the virus enters cells, with the highest receptor levels found in the brush border of intestinal enterocytes. Surprisingly, virus infected both high- and low expressors of ACE2, and infectivity of organoids was not greatly affected by culture conditions.

SARS-CoV-2 rapidly infected a subset of cells within the organoid, and infection increased over time. Using electron microscopy to visualize cellular components, the researchers found virus particles inside and outside the organoids constituent cells. Infection induced release of interferon, an endogenous antiviral whose activation could serve as the target for potential therapies.

The researchers concluded that intestinal epithelium supports SARS-CoV-2 replication, that human small intestinal organoids serve as an experimental model for coronavirus infection and biology, and that human organoids represent faithful experimental models to study the biology of coronaviruses.

In addition to drug screening and toxicology studies, airway organoids have been utilized to study the basic biology of infectious diseases. In an application note, Corning scientists reported that Corning Matrigel extracellular matrix facilitated the expansion of patient-derived bronchial epithelial cells into airway organoids suitable for high throughput analysis. Organoids streamlined the usual sample preparation protocol to a single operation cell lysis eliminating the normal steps of gene amplification, cDNA conversion, and library preparation.

Comparing normal and asthmatic airway organoids, investigators observed increased expression of genes coding for pro-inflammatory chemokines, receptors, and other proteins associated with inflammation in asthmatic airway cells. They also found that the genes upregulated in organoids derived from healthy cells were the same as those downregulated in organoids from asthmatic cells, and vice-versa. Application of the anti-inflammatory steroid dexamethasone induced up- or downregulation to a greater degree in asthmatic organoids compared with normal organoids.

The Corning study illustrates the versatility of organoids for studying airway diseases in the presence of comorbidities, as well as the ability to respond rapidly with suitable models for infectious diseases.

HUB Organoids derived from adult stem cells harvested from cystic fibrosis patients have proved valuable in the study of CF pathology, and have permitted patient-centered drug testing, which was the first use of HUB Organoids in personalized medicine. The CF patient derived organoids are tested to identify drug treatments for CF patients and in treated accordingly.

Recent studies on interleukin-17 receptors on lung epithelia have uncovered a role for this cytokine in acute and chronic inflammation, and demonstrated that IL-17 receptors participate in the innate immune defense against pulmonary fungal infections. In vivo, IL-17 expression and immune function requires polarized epithelial cells. In a paper appearing in 2019 in Frontiers in Immunology, a group at the University of Perugia, in Italy, wrote that because lung organoids recapitulate tissue polarity, they provide an exciting possibility of using lung organoids to comprehensively investigate IL-17R signaling in the lung, which is likely to offer new opportunities to develop and test therapeutics for inflammatory diseases and identify new molecular targets to improve resistance to infections.

As a scientific discipline, organoids will continue evolving towards greater ease of use, consistency, assay parallelism capabilities, and manufacturability. Organoids and organ-on-a-chip have already been combined in a complex, multi-tissue retina model, while systems consisting of organoids from two or more organs, discussed earlier, are already used routinely.

If organoid research continues at its current pace there is reason to expect significant streamlining of early-stage drug development, specifically around the preclinical and phase 1 stages. Organoids could eliminate some if not all animal testing, but this will require a leap of faith on the part of regulators already accustomed to reviewing animal data and its inherent caveats. At some point organoids might completely eliminate live preclinical screens, allowing drug developers to recruit patients directly into phase 2 based entirely on organoid-based screening.

While organoid investigations inevitably lead to systems of greater complexity, investigators should keep in mind that validation is the key to patient relevant models. HUB Organoids for the first time allow researchers to develop a model and directly test if and how it resembles the patient from which the tissue originated. With increasing complexity, the validation step should remain a focus of model developers and users. Complexity is good, but only up to a point.

Advancing organoids towards these lofty goals, including greater manufacturability, will require cell culture tools up to the task. Industry collaborations assure that tools for 3D cell culture will continue to advance, both for general research and to meet the challenges of emerging infectious diseases.

Authors: Dr Robert Vries, Chief Executive Officer, Hubrecht Organoid Technology (HUB)Elizabeth Abraham, Senior Product Manager, Corning Incorporated

Excerpt from:
Using Organoids in the Study of Infectious Diseases - Technology Networks

New York, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biotechnology Instrumentation Industry" - https://www.reportlinker.com/p090668/?utm_source=GNW 4 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. Immunoassay Systems, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$21.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the DNA Sequencing Systems segment is readjusted to a revised 8.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 5.3% CAGR

The Biotechnology Instrumentation market in the U.S. is estimated at US$12.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$11 Billion by the year 2027 trailing a CAGR of 5.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 4.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Mass Spectrometry Segment to Record 6.8% CAGR

In the global Mass Spectrometry segment, USA, Canada, Japan, China and Europe will drive the 6.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.9 Billion in the year 2020 will reach a projected size of US$6.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.2 Billion by the year 2027.We bring years of research experience to this 19th edition of our report. The 233-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p090668/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Biotechnology Tools - Driven by Advancements Recent Market Activity Global Market Analysis Factors Sustaining Market Growth Factors Restraining Growth Improving Economy Signals Market Growth Opportunities Global Competitor Market Shares Biotechnology Instrumentation Competitor Market Share Scenario Worldwide (in %): 2018 & 2029 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS Abbott Laboratories (USA) Agilent Technologies, Inc. (USA) Beckman Coulter, Inc. (USA) Bio-Rad Laboratories, Inc. (USA) Bruker Corporation (USA) GE HealthCare (UK) Gilson, Inc. (USA) Harvard Bioscience, Inc. (USA) Hitachi High-Technologies Corp. (Japan) Illumina, Inc. (USA) Lonza Group AG (Switzerland) PerkinElmer, Inc. (USA) Roche Diagnostics (Switzerland) Shimadzu Corp. (Japan) Siemens Healthineers (USA) Thermo Fisher Scientific, Inc. (USA) Waters Corp. (USA)

3. MARKET TRENDS & DRIVERS DNA Sequencing Future Diagnostic Applications of DNA Sequencing Next-Generation Sequencing Technologies Drive the Momentum Liquid Chromatography Growth in New Application Markets HPLC Offers Significant Growth Opportunities Innovative HPLC Products Inject New Growth Ultra-High Pressure Liquid Chromatography MS Systems with UHPLC Advancements in HPLC Columns Electrophoresis Systems Capillary Gel Electrophoresis - Gains Prominence Product Innovations Sustain Sales Immunoassay Instruments Growth Opportunities and Areas Automated Multiplexing Platforms Present Growth Opportunities Radioimmunoassay Systems Lose Ground Chemiluminescence Immunoassays Gain Demand Mass Spectrometry Technological Developments and Expanding End-Use Applications to Bolster Growth A Review for Select MS Technologies Portability: A Major Driving Force for MS Systems Market Nanotube Coating to Enable Miniaturization in Mass Spectrometers High Prices of MS Systems Hold Down Sales Growth Purpose-Built Mass Spectrometers to Transform Personalized Medicine Lack of Suitable Software and Diversity of MS Systems - A Major Challenge Smaller Clinical Laboratories Continue to Shy Away from Mass Spectrometers Microarrays Protein Biochips - Set for Robust Expansion Lab-on-a-Chip: Fusion of Nanotechnology & Genetic Engineering Advancements in Biochip Technology Biochip Technology Boosts Personalized Medicine Biochip Technology Spreads beyond Pharma Industry Data on Specificity of Effect Drives Use of Microarrays in Cosmetics and Personal Healthcare Laboratory Automation Technology Sets the Momentum for Microplate Reader Market Growing Options in Multimode Microplate Readers

4. GLOBAL MARKET PERSPECTIVE Table 1: Biotechnology Instrumentation Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 2: Biotechnology Instrumentation Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019

Table 3: Biotechnology Instrumentation Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027

Table 4: Immunoassay Systems (Product Segment) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 5: Immunoassay Systems (Product Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 6: Immunoassay Systems (Product Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

Table 7: DNA Sequencing Systems (Product Segment) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027

Table 8: DNA Sequencing Systems (Product Segment) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019

Table 9: DNA Sequencing Systems (Product Segment) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027

Table 10: Mass Spectrometry (Product Segment) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027

Table 11: Mass Spectrometry (Product Segment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019

Table 12: Mass Spectrometry (Product Segment) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 13: MicroArrays (Product Segment) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027

Table 14: MicroArrays (Product Segment) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 15: MicroArrays (Product Segment) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

Table 16: Liquid Chromatography Systems (Product Segment) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 17: Liquid Chromatography Systems (Product Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 18: Liquid Chromatography Systems (Product Segment) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 19: Laboratory Automation (Product Segment) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020 to 2027

Table 20: Laboratory Automation (Product Segment) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 21: Laboratory Automation (Product Segment) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027

Table 22: Electrophoresis Systems (Product Segment) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2020 to 2027

Table 23: Electrophoresis Systems (Product Segment) Global Historic Demand in US$ Thousand by Region/Country: 2012 to 2019

Table 24: Electrophoresis Systems (Product Segment) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 25: Other Product Segments (Product Segment) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 26: Other Product Segments (Product Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 27: Other Product Segments (Product Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Market Facts & Figures US Biotechnology Instrumentation Market Share (in %) by Company: 2018 & 2025 Market Analytics Table 28: United States Biotechnology Instrumentation Market Estimates and Projections in US$ Thousand by Product Segment: 2020 to 2027

Table 29: Biotechnology Instrumentation Market in the United States by Product Segment: A Historic Review in US$ Thousand for 2012-2019

Table 30: United States Biotechnology Instrumentation Market Share Breakdown by Product Segment: 2012 VS 2020 VS 2027

CANADA Table 31: Canadian Biotechnology Instrumentation Market Estimates and Forecasts in US$ Thousand by Product Segment: 2020 to 2027

Table 32: Canadian Biotechnology Instrumentation Historic Market Review by Product Segment in US$ Thousand: 2012-2019

Table 33: Biotechnology Instrumentation Market in Canada: Percentage Share Breakdown of Sales by Product Segment for 2012, 2020, and 2027

JAPAN Table 34: Japanese Market for Biotechnology Instrumentation: Annual Sales Estimates and Projections in US$ Thousand by Product Segment for the Period 2020-2027

Table 35: Biotechnology Instrumentation Market in Japan: Historic Sales Analysis in US$ Thousand by Product Segment for the Period 2012-2019

Table 36: Japanese Biotechnology Instrumentation Market Share Analysis by Product Segment: 2012 VS 2020 VS 2027

CHINA Table 37: Chinese Biotechnology Instrumentation Market Growth Prospects in US$ Thousand by Product Segment for the Period 2020-2027

Table 38: Biotechnology Instrumentation Historic Market Analysis in China in US$ Thousand by Product Segment: 2012-2019

Table 39: Chinese Biotechnology Instrumentation Market by Product Segment: Percentage Breakdown of Sales for 2012, 2020, and 2027

EUROPE Market Facts & Figures European Biotechnology Instrumentation Market: Competitor Market Share Scenario (in %) for 2018 & 2025 Market Analytics Table 40: European Biotechnology Instrumentation Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027

Table 41: Biotechnology Instrumentation Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019

Table 42: European Biotechnology Instrumentation Market Share Shift by Region/Country: 2012 VS 2020 VS 2027

Table 43: European Biotechnology Instrumentation Market Estimates and Forecasts in US$ Thousand by Product Segment: 2020-2027

Table 44: Biotechnology Instrumentation Market in Europe in US$ Thousand by Product Segment: A Historic Review for the Period 2012-2019

Table 45: European Biotechnology Instrumentation Market Share Breakdown by Product Segment: 2012 VS 2020 VS 2027

FRANCE Table 46: Biotechnology Instrumentation Market in France by Product Segment: Estimates and Projections in US$ Thousand for the Period 2020-2027

Table 47: French Biotechnology Instrumentation Historic Market Scenario in US$ Thousand by Product Segment: 2012-2019

Table 48: French Biotechnology Instrumentation Market Share Analysis by Product Segment: 2012 VS 2020 VS 2027

GERMANY Table 49: Biotechnology Instrumentation Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product Segment for the Period 2020-2027

Table 50: German Biotechnology Instrumentation Historic Market Analysis in US$ Thousand by Product Segment: 2012-2019

Table 51: German Biotechnology Instrumentation Market Share Breakdown by Product Segment: 2012 VS 2020 VS 2027

ITALY Table 52: Italian Biotechnology Instrumentation Market Growth Prospects in US$ Thousand by Product Segment for the Period 2020-2027

Table 53: Biotechnology Instrumentation Historic Market Analysis in Italy in US$ Thousand by Product Segment: 2012-2019

Table 54: Italian Biotechnology Instrumentation Market by Product Segment: Percentage Breakdown of Sales for 2012, 2020, and 2027

UNITED KINGDOM Table 55: United Kingdom Market for Biotechnology Instrumentation: Annual Sales Estimates and Projections in US$ Thousand by Product Segment for the Period 2020-2027

Table 56: Biotechnology Instrumentation Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product Segment for the Period 2012-2019

Table 57: United Kingdom Biotechnology Instrumentation Market Share Analysis by Product Segment: 2012 VS 2020 VS 2027

REST OF EUROPE Table 58: Rest of Europe Biotechnology Instrumentation Market Estimates and Forecasts in US$ Thousand by Product Segment: 2020-2027

Table 59: Biotechnology Instrumentation Market in Rest of Europe in US$ Thousand by Product Segment: A Historic Review for the Period 2012-2019

Table 60: Rest of Europe Biotechnology Instrumentation Market Share Breakdown by Product Segment: 2012 VS 2020 VS 2027

ASIA-PACIFIC Table 61: Biotechnology Instrumentation Market in Asia-Pacific by Product Segment: Estimates and Projections in US$ Thousand for the Period 2020-2027

Table 62: Asia-Pacific Biotechnology Instrumentation Historic Market Scenario in US$ Thousand by Product Segment: 2012-2019

Table 63: Asia-Pacific Biotechnology Instrumentation Market Share Analysis by Product Segment: 2012 VS 2020 VS 2027

REST OF WORLD Table 64: Rest of World Biotechnology Instrumentation Market Estimates and Forecasts in US$ Thousand by Product Segment: 2020 to 2027

Table 65: Rest of World Biotechnology Instrumentation Historic Market Review by Product Segment in US$ Thousand: 2012-2019

Table 66: Biotechnology Instrumentation Market in Rest of World: Percentage Share Breakdown of Sales by Product Segment for 2012, 2020, and 2027

IV. COMPETITION Total Companies Profiled: 131Read the full report: https://www.reportlinker.com/p090668/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
Global Biotechnology Instrumentation Industry - GlobeNewswire

Thursday, August 27, 2020

In this episode, Foley PartnersJudy WaltzandAntoinette Konskitalk withEdward Abrahams, the President of the Personalized Medicine Coalition, to discuss the issues facing personalized medicine and how the concepts underpinning the field may be applied to diagnose and treat COVID-19.

We encourage you to listen to thepodcast in its entirety.

Following is a transcript of this podcast. Please feel free to download aPDF version here.

Please note that theinterview copy below is not verbatim. We do our best to provide you with a summary of what is covered during the show. Thank you for your consideration, and enjoy the show!

Personalized or precision medicine is the field of medicine that finds the best treatment for each patient at the right time. Physicians use diagnostic tests, medical history, circumstances, and values, as well as information from prior patient therapies, to prevent disease and develop targeted therapies that can expedite a patient's treatment and recovery.

The Personalized Medicine Coalition, or PMC, is an advocacy and educational group that represents innovators, scientists, patients, providers, and payers to promote the understanding and adoption of personalized medicine concepts, services, and products. Dr. Edward Abrahams is the president of the PMC and has charted its growth from its original 18 founding members in 2004 to more than 200 members today.

I am pleased to have Ed as our guest to explore issues facing personalized medicine and how its concepts and emerging research may be applied to diagnose and treat COVID-19. Ed, thank you so much for being with us here today. Did I hit the mark on precision medicine? Is there anything you would like to add by way of introduction to yourself or the PMC?

I think you have defined personalized medicine very well indeed. Let me begin by noting, as you just did, that I have never met a patient who did not prefer getting the right medication the first time, rather than going through a process of trial and error because the right diagnosis could not be made in advance of selecting the right therapy.

The good news is that we have many more molecular diagnostics today to target the right treatments to the right patients at the right time, as is often said. But personalized medicine also promises lower costs for systems that incorporate the tests and treatments underpinning the field into their clinical work streams. This is very important. By becoming more efficient with targeted therapeutics and avoiding costly interventions that don't work, personalized medicine can help these systems save money, and, at the same time, provide better outcomes for individual patients.

In other words, and this is terribly important in today's context of constricted resources for health care, with personalized medicine, we can enjoy the benefits of innovation and reduce costs. But we have to be smart about how we develop these opportunities. At present, we have only anecdotal evidence that personalized medicine can deliver both clinical and economic benefits, which is why PMC is doing the research to demonstrate that even if individual therapies come with high price tags, as many in fact do, they can and will produce cost savings if we target them to only those patients who will benefit.

That, in brief, is the real promise of personalized medicine. We believe personalized medicine can provide tremendous value, not only to patients, but also to the systems and countries that in fact have the courage to implement it.

Thank you so much for that explanation and background on personalized medicine and how it is being used today to treat and prevent disease. Ed, for me, one of the highlights of the year is the publication of PMC's annual report that summarizes the key advances the industry has made over the past year. When will the 2020 edition be released, and can you give us a preview of what to expect?

Within the next eight weeks, the Personalized Medicine Coalition will publish the sixth edition ofThe Personalized Medicine Report. We used to call itThe Case for Personalized Medicine, but we now believe that the case has been made.

The report is our effort to define the field by explaining personalized medicine's opportunity, documenting its status, and discussing the challenges it faces. It's a widely read report that is written for laymen, particularly policymakers at federal agencies and on Capitol Hill.

The sixth edition will, for example, show that in 2008, there were only five personalized medicines, which we define as therapeutics with biomarker strategies on their labels, on the market. Today, there are over 250, so you can see there's been enormous progress over these past 10 years or so.

While most of these products are in oncology, we have also seen progress in other indications as well, including cardiovascular illness, depression, and especially rare diseases. The report will also show that today there are 75,000 genetic testing products on the market, up from fewer than 66,000 in 2016. In other words, this is an exploding field.

Also new in this report are discussions of how advanced analytics, artificial intelligence, and machine learning are yielding new insights about how other biological and environmental factors, in addition to genetics, influence a patient's disease risk and response to various treatments, thus opening the door to preventive medicine, one of personalized medicines most important if as yet unrealized promises.

The report documents how, by targeting effective treatments to those patients who benefit, personalized medicine can achieve key goals for patients and health systems. It can shift the emphasis in medicine from reaction to prevention with emerging technologies like liquid biopsies, which may be able to detect cancer before any symptoms occur. This is tremendously important and a great promise. It may reduce trial-and-error prescribing, which patients would absolutely love.

Personalized medicine can also cut the number of adverse drug reactions, which right now are the third or fourth largest cause of death in the United States. It can use cell-based or gene therapy to replace or circumvent molecular pathways associated with disease, thereby offering cures where none had existed before. It can reveal additional targeted uses for medicines and drug candidates. It will obviously increase patient adherence to treatment, as patients will be more likely to stay on medications that don't have dangerous side effects, for example.

Personalized medicine will also reduce high-risk invasive procedures, which it already has done in say, kidney transplants, for example. It will help move patient-physician engagement toward patient-centered care. And finally, as I mentioned, it could and should reduce the overall cost of health care.

The report makes the argument that outstanding challenges in regulation, reimbursement, and clinical adoption slow our efforts to capitalize on advances made possible by personalizing treatments. Overcoming these obstacles, as we write, will require a collaborative effort to keep up with the pace of progress in science and technology. And this is in fact the overall mission of the Personalized Medicine Coalition.

At the end of the dayand you mentioned this a bit in your commentsfor personalized medicine to be a success and available to patients, it has to be adopted by the clinicians. How does that happen, and are there obstacles to that success?

This is a key thrust of the Personalized Medicine Coalition because we are learning that clinical adoption is a much slower process than patients want and expect. For example, PMC will publish a study this week documenting that medically appropriate genomic testing is quite inconsistent across the United States.

That means, for example, that some patients in cancer are not getting available treatments they need. The study shows that coverage and reimbursement strategies are not the only barriers to personalized medicine, as you might expect. Other barriers include lack of awareness among providers and patients, not to mention socioeconomic factors, including distance and access issues.

In medicine, it doesn't necessarily follow that if you build it, they will come. There are many mediators along the way from discovery and development to adoption. We also know from another PMC-commissioned study of the value of genomic testing in cancer care, for example, that many patients who are eligible for effective targeted therapies, as determined by genomic sequencing of their tumor, still do not receive the best treatment option based on the results.

This practice gap can be attributed to the limitations in the availability and interpretation of test results, sample processing constraints, limited access to targeted therapies, and especially lagging awareness of the rapidly evolving field of personalized medicine among physicians and other providers.

We demonstrate in this study that if all patients who were eligible to receive a targeted treatment actually received it, the cost-effectiveness of genomic sequencing, which is sometimes alleged to be too high, would significantly improve. In short, along with public policy, we know that the downstream issues focused on clinical adoption are extremely important and must be addressed.

We are in a continuing debate with respect to drug pricing in the United States. How does that debate impact the future of personalized medicine and how would you address or make some recommendations as to how we price our drugs?

That's a very important question because as you know, the drug pricing debate has gripped public attention. But we are not considering all ramifications. The debate has particular implications for the development of personalized medicines, which tend to be more expensive but may together have a positive impact on the health care system and on overall costs.

We have to ensure that innovative products remain accessible, including to those who cannot afford them. But we also have to be careful not to remove the incentives to discover and develop those products in the first place, which I am afraid that price controlsno matter how they are implementedwould do. That is to say, they would stifle innovation. Drug development is a risky business. There are no guarantees. If we move or decrease the financial incentive to find new cures to unmet medical needs, it follows that we're going to see fewer interventions.

Late last month, President Trump issued an executive order to tie the prices paid for physician-administered drugs, many of which are personalized medicines, to those that are paid in other countries. That may be politically popular because those other countries pay less. But the policy, if implemented, will have disastrous unintended consequences for the development of say, new cell-based therapies, gene therapies, and targeted medicines that are only now reshaping health care in ways no one thought possible ten years ago.

This is so because there are incentives in place to encourage the development of groundbreaking therapies. It's important to understand that when a pharmaceutical company invests in, say, finding a one-shot cure for spinal muscular atrophya rare and debilitating disorder that affects fewer than 25,000 people in the United Statesit does so without any guarantee of success, and it does so also with very high up-front costs that must be recovered. If the company that develops the cure cannot get a return on its investment, it's unlikely to take these big risks upon which patients depend. Long story short, patients will suffer and the costs of providing carenot curesfor those patients will remain higher than they could be.

I'd like your opinion on a topic of current urgent and global concern. Today, we are challenged medically and economically with the COVID-19 pandemic. How have the principles of personalized medicine been applied to diagnosing and treating COVID-19?

I actually believe that the principles of personalized medicine that emphasize stratified responses, even when it comes to public health, have significant implications for diagnosing and treating COVID-19. Those principles, I believe, should inform future interventions to stem this terrible pandemic that has already killed over 170,000 people in the United States alone.

I don't think these principles are being adequately considered as part of the debate. PMC looks forward to introducing those principles, because they're so very important if we're going to effectively address this pandemic.

First, we have been very slow to develop and deploy real-time diagnosticsthe backbone of personalized medicine. These diagnostics give us the tools to determine who is at risk, so we don't have to put in place one-size-fits-all public health responses, including closing down whole economies, when that might not be necessary if we knew who had the disease or who was likely to get the disease.

To date, we have not been able to target long-term prevention and treatment plans to the most at-risk populations, which would be enormously helpful in reopening economies, which we would obviously like to do sooner than later.

Second, and equally important, we know that the coronavirus expresses itself differently among different populations. For example, older men, racial and ethnic minorities, and those with particular underlying conditions seem to be more vulnerable to disease. It behooves us, therefore, to understand the molecular and environmental reasons for this differentiated response, and to develop and deploy therapies and vaccines that are targeted to those who are in need.

Today, we are looking for one-size-fits-all solutions because there's an urgency to find one. But eventually, scientists in my opinion are going to recognize that, because not everyone responds the same, different medicines are going to have to be developed to treat COVID-19 and other viruses.

We've already seen this in AIDS, and so I don't think the coronavirus is going to be different. We have to be really smart about how we address this pandemic. By the way, on September 3rd, PMC is organizing a virtual seminar, titledCOVID-19 and Personalized Medicine: Current Status and Lessons Learned. It is free, and if you want to register, you can do so on ourwebsite.

Ed, thank you so much for being with us today, and as we wrap up, I'd like to invite you to make any closing remarks or comments on the topics we covered today.

I'd really like to thank you both for your loyal support to the Personalized Medicine Coalition, and for giving me the opportunity to discuss these very important issues with your audience. I hope people will pay attention to personalized medicine. We believe it represents the future, and we also believe that if we invest in it, if we come together collaboratively as a community, we can have a health care system that we deserve based upon the developments in science and technology, which have never been more promising. Again, thank you for your attention, and I look forward to working with you and everybody on this podcast to move this field forward. It's not going to happen by itself.

Here is the original post:
COVID-19 & Healthcare: Personalized Medicine is the Future - The National Law Review

With the recent death of actor Chadwick Boseman, many may be wondering how a seemingly healthy adult is diagnosed with a disease often thought of as illness of older adults. Although colorectal cancer is most often diagnosed in people 50 years or older and incidence rates in this age group are, in fact, declining, the number of adults under 50 diagnosed with colorectal cancer is rising. According to the National Cancer Institute, approximately 5 percent of all new cases of colorectal cancer in the United States are among persons 15 to 39 years old.

African Americansbear a disproportionate burden of cancer. Studies have shown that those who are diagnosed with colorectal cancer at a young age have worse survival outcomes compared to young white patients.

With improvements in prevention, early detection and treatment, there are more than 1.5 million colorectal cancer survivors living in the U.S. Still, an estimated 53,200 people will die this year, making this disease the third most deadly cancer among men and women in the U.S. Approximately 147,950 people will be diagnosed in 2020. Thats one in 23 men and one in 25 women who will develop colon or rectal cancer, the two malignancies that make up colorectal cancer.

At UC San Diego Health, a comprehensive team of medical, surgical and radiation oncologists use the most advanced treatment options, such as laparoscopic surgery and personalized medicine. At Moores Cancer Center, patients can enroll in clinical trials specifically for colorectal cancer.

Oncologists with Moores Cancer Center are available to answer questions about this disease.

###

Follow this link:
Is 43 Too Young for Colon Cancer? UC San Diego Health Experts Available to Talk About Colorectal Cancer - Newswise

Nanotheranostics, integrating diagnostic and therapeutic functions by nanoplatform, exhibits a great potential in precision and personalized medicine, and also raises the requirement on multifunctional nanomaterials in pursuit of both good biocompatibility and high theranostic performances. The emergence of diverse multifunctional nanomaterials and advanced nanotechnologies unprecedentedly simulates the evolution of nanotheranostics, and enables the integration of multimodal imaging and therapeutic functions in a single theranostic nanoparticle for high-efficacy theranostics of diseases. In engineering of theranostic nanoplatforms, biocompatibility and multifunction are two most important factors which need to be considered. Among various nanotheranostics, multimodal imaging-guided photothermal therapy has attracted intensive attention owing to its less invasiveness and lower side effects compared with conventional radiotherapy and chemotherapy.

In a new article published in the Beijing-based National Science Review, scientists in Shenzhen University, China, hypothesize that controllable incorporation of biocompatible Se element into the lattice of Te nanostructures for construction of TeSex nano-alloys could intrinsically tune the inherent cytotoxicity of Te nanomaterials, enhance the biocompatibility of Te nanomaterials and extend their functions for biomedical applications. In this work, a series of TeSex nano-alloys with different Se incorporating proportions are synthesized to investigate their biocompatibility and develop their theranostic functions. It is determined that the toxicity of Te nanomaterials mainly comes from irreversible oxidation stress and intracellular imbalance of organization and energy, which is exterminated by the nano-alloying by incorporating a moderate proportion of Se (x=0.43). The synthesized TeSex nano-alloy exhibits extraordinarily high NIR-II-photothermal conversion efficiency (77.2%), 64Cu coordination and CT contrast capabilities, enabling high-efficacy photothermal therapy of cancer under the guidance of multimodal PT/PA/PET/CT imaging.

Several main advances are achieved. (1) Advanced TeSex nano-alloys are facilely constructed to intrinsically eliminate the inherent toxicity of Te nanomaterials by the moderate incorporation of biocompatible Se. (2) Advanced mechanisms for Te nanomaterial toxification and TeSex alloying detoxification are uncovered. (3) Advanced theranostic performances with ordinarily high NIR-II-photothermal efficiency and multimodal PT/PA/CT/PET imaging capability are achieved by proposed nano-alloying strategy.

See the article here:
Biocompatible TeSex nano-alloys for PT/PA/CT/PET imaging-guided NIR-II-photothermal therapy - Science Codex

SARASOTA, Fla., Sept. 1, 2020 /PRNewswire/ --Transcendent Publishing today announced the release of Male 2.0: Cracking the Code to Limitless Health and Vitality by author Tracy Gapin, MD, FACS. Since its August release, the book has already reached Amazon bestseller status. Dr. Gapin, a men's health and performance expert and member of the American Urological Association, provides a meaningful impact for men's health with this leading-edge approach.

Over the past thirty years, there has been a relentless population-based decline in mens' testosterone levels by over thirty percent. We've also seen a dramatic increase in the incidence of obesity. Over seventy percent of men are either overweight or obese, which is directly tied to energy, productivity, and overall health and performance. This has led to a men's health epidemic for the 159 million men in the United States.

The Male Method described throughout Male 2.0 was developed to help men lose weight, regain energy, optimize their hormones, and regain peak performance. "We need to go beyond testosterone. We need to take an individualized, systems-based approach to optimize men's health, performance and longevity," says Tracy Gapin, MD, FACS. "Driven by the power of epigenetics, genetics, peptides, and wearable technologies, we have gained incredible insight into some of the most misunderstood aspects of men's health and longevity."

JJ Virgin, New York Times Bestselling author of The Virgin Diet & Sugar Impact Diet said, "As a thought leader in men's health, Dr. Gapin has provided the modern-day blueprint to help men optimize their health and regain their vitality. Every man should read this book."

Clete Walker, CEO of Vituro Health, a prostate health company, said, "Male 2.0 is a revolution for men's health. After my father was diagnosed with prostate cancer, I made it my mission to seek out potential new modalities, and this data-driven approach is the future."

Male 2.0: Cracking the Code to Limitless Health and Vitalityis available on Amazon and during the month of September the print version is available for free at The Gapin Institute. http://www.GapinInstitute.com

About Tracy Gapin, MD FACS:Dr. Gapin is board-certified Urologist, world renowned Men's Health & Performance Expert, Author, and Professional Speaker. Using state-of-the-art biometric monitoring, nutrition and lifestyle intervention, Dr. Gapin coaches Fortune 500 executives and evolutionary leaders of business, sports medicine, and high performance. He specializes in cutting-edge precision medicine with an emphasis on epigenetics, providing men with a personalized path to optimizing health & performance. http://www.GapinInstitute.comEmail: [emailprotected]

About Transcendent Publishing:Since 2012, Transcendent Publishing has specialized in offering a variety of publishing and design services for today's indie author. http://www.transcendentpublishing.com

CONTACT:Leann Spofford[emailprotected]Tel: (941) 524-4592

SOURCE Gapin Institute

Home – MMG

See the article here:
Men's Health Expert Tracy Gapin, MD Unveils Male 2.0 with a Revolutionary Protocol to Conquer the Men's Health Epidemic - PRNewswire

A postdoctoral position is available at the Faculty of Medicine, University of Helsinki, Finland to work in the research group of Dr. Jing Tang (https://www.helsinki.fi/en/researchgroups/network-pharmacology-for-preci...). The position is part of an Academy of Finlands research project that aims to do network pharmacology modeling to provide the mechanism of action of drugs and drug combinations for a systems-level understanding of cancer. The Tang group combines computational methods to offer improved efficiency methods to identify more effective cancer treatments for personalized medicine. The Tang laboratory is based at Research Program in Systems Oncology (ONCOSYS) (https://www.helsinki.fi/en/researchgroups/research-program-in-systems-on...) at the Meilahti biomedical campus.

Role description:

We are seeking at least one postdoctoral researcher to work on the computational methods to develop network pharmacology models for predicting drug combinations. The project is focused on strategies for predicting potential drug combination and patient subclasses by constructing multipartite networks using drug response data. The primary goal of the project is to analyse drug sensitivity datasets to exploit drug-target interaction data to explore the biological mechanism of drugs. A key aim of the work is to propose drug combination regimens focusing on patient-derived drug response data along with the providing a biochemical and biophysical understanding of a drug combination. Hematological malignances and ovarian cancer are the available datasets for this project. The post holder will be responsible for planning and conducting computational research within the project under the supervision of Dr. Mohieddin Jafari, and Prof. Jing Tang.

The ability to work well within a collaborative team is critical for this position. You will work with unique datasets derived from large-scale experiments associated with a diverse range of projects in pharmacology and molecular biology. Salary will be commensurate with qualifications and experience based on the University guidelines. The full-time position start Jan 2021. A six-month trial period will be applied.

Key requirements:

We are seeking a creative and highly motivated individual with primary interest in network science and biomedical data mining. Candidates should have a PhD in bioinformatics, computational biology, statistics, computer science or other related disciplines. The ideal candidate will have experience in at least one of the aforementioned areas, and a strong interest in the others. Previous experience with biological networks, omics datasets, and expertise in related statistics and modelling are considered an advantage. Solid skills in scripting/programming (preferably R and Python) are essential prerequisites for this position. Excellent communication and presentation skills in English, good organisational skills, troubleshooting expertise and the ability to work effectively to tight deadlines are desirable.

Appointment details:

The position is available from October 2020 onwards, and can be started later upon agreement. It is a two-year fixed-term position, with a possibility of extension. Trial period of 6 months will be applied. The salary will be based on level 5 of the demands level chart for teaching and research personnel in the salary system of Finnish universities. In addition, the appointee will be paid a salary component based on personal performance with the overall starting salary amounting to approximately 3300-3600 EUR per month, depending on the qualifications and previous relevant research experience of the candidate.

Application details:

Please submit your application via the University of Helsinki Recruitment System by clicking the Apply for the position button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment@helsinki.fi.

Please attach the following documents to your application as a single PDF file:

The deadline for applications is September 30th 2020. Interviews will be conducted either in person or online. For more information on the position, please contact Dr. Mohieddin Jafari (mohieddin.jafari(at)helsinki.fi) and Prof. Jing Tang (jing.tang(at)helsinki.fi).

The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.

Together with the Helsinki University Hospital (HUS) and the Helsinki Institute of Life Sciences (HiLIFE), the Faculty of Medicine, University of Helsinki, constitutes the Academic Medical Center Helsinki (AMCH). This medical center has been very successful in international comparisons, ranking among the top 10 medical campuses in Europe and among the top 50 globally.

Research Program in Systems Oncology (ONCOSYS) consists of basic, translational and clinical researchers who use cutting-edge measurement technology, patient data and AI methods in cancer research and oncology. The overall objective of ONCOSYS is to understand the underlying causes of cancer progression or treatment resistance, and to develop effective diagnostic, prognostic and therapeutic approaches.

Due date

30.09.2020 23:59 EEST

Read the original:
Postdoctoral Researcher in Biological Network Modelling job with UNIVERSITY OF HELSINKI | 223494 - Times Higher Education (THE)

West Palm Beach, FL, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Medical Practice Income (MPI), a subsidiary of USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce the early success of the QHSLab launch in South Florida. Since launching the platform on June 30, 2020, 159 medical practices have provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in reimbursement revenue to these physicians practices.

There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States. Many are reporting higher rates of fatigue and burnout due to long hours, heavy patient caseloads, and declining practice revenue from a lack of healthcare reimbursements. Primary care physicians are particularly overwhelmed by the number of patients suffering from allergies, which often signal other health related and immune compromising concerns. Doctors need smart, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. With the addition of QHSLab, not only will physicians be better equipped to treat patients, but they will also be able to sustain their practices with ongoing revenue through healthcare reimbursements, generating new income per practice, per year.

Allergies alone are estimated to affect 1 in every 5 Americans and costs upwards of $18 billion in direct health and medical expenditures annually. It not only impairs quality of life, but is responsible for as much as $4 billion annually in lost productivity due to work and school absences. When over-the-counter allergy medication treatment is no longer successful, allergen immunotherapy is recommended. Allergen immunotherapy is usually prepared by allergy specialists however, today there is a published shortage of board-certified allergy specialists available to treat the number of allergy sufferers.1 Patients must now rely on their primary care provider to effectively manage their allergies. Through our AI-enhanced, physician-directed platform, MPIs QHSLab, were increasing the primary care physicians ability to effectively address their patients chronic conditions, while saving them time and potentially expensive visits to a specialist when not absolutely necessary, said Troy Grogan, President and CEO of Medical Practice Income, Inc and USA Equities Corp.

The Fall of 2020 is soon upon us, but this season will be even more alarming than usual due to the ongoing spread and impact of COVID-19. Fredric Pullen MD, FACS, an Allergy and Ear, Nose & Throat Specialist based in Palm Beach Gardens, FL shared the following insight regarding QHSLab: Its so much easier for busy primary care physicians to have a software system that can automatically generate the patients allergy formulas for their appropriate immunotherapy, based on their allergy test results. It saves time and potential error which is a definite plus for non-allergy specialist doctors, especially in the age of COVID-19.

For more information about Medical Practice Income, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.

About USA Equities Corp (OTC Link: USAQ)

On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Companys intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit http://www.MedicalPracticeIncome.com/discover.

Forward-Looking Statements

This press release contains forward-looking statements which are identified by words such as may, could, believes, estimates, targets, expects, or intends and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the Risk Factors section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.

Read more from the original source:
Medical Practice Income, Inc., a Subsidiary of USA Equities Corp. (USAQ), Announces the Early Success of QHSLab Launch in South Florida -...

SAN FRANCISCO, Aug. 31, 2020 /PRNewswire/ -- The global lab supplies marketsize is expected to reach USD 49.6 billion by 2027, expanding at a CAGR of7.1%,according to a new report by Grand View Research, Inc. Focus on R&D drives the demand for lab equipment market, thereby boosting the market growth.

In June 2019, the D.O.D's Defense Logistics Agency settled the bidding process for USD 312.0 million contracts, for lab equipment and supplies. There are instances of huge government spending in the category including White House's budget of 2020 that provides USD 134.0 billion for federal R&D, including significant investments in R&D facilities and equipment.

Key suggestions from the report:

Read 120 page research report with ToC on "Lab Supplies Market Size, Share & Trends Analysis Report By Product (Equipment (Autoclaves & Sterilizers, Lab Air Filtration System), Disposables (Tubes, Gloves)), By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/laboratory-supply-market

Laboratories have emerged as multipurpose research facilities in which various types of testing mechanisms, research analogies, and novel developments are carried out. This has also led to an increase in the demand for lab equipment and supplies market. Furthermore, the trend of research-based studies has been gaining traction over the past decade. This has resulted in the development of new laboratories in academic institutes, thereby boosting the market growth.

Recently, clinical laboratories have also gone through major technological advancements. With intense R&D going in the field of the pathogenesis of diseases and personalized medicine, advanced diagnostics methods and tests are being implemented extensively. Technological improvements in instrumentation continue to bring real benefits that accrue from greater ease of use, increased capacity, speed of analysis, higher precision, operational efficiencies, enhanced reliability, improved safety, and numerous other intangibles.

Grand View Research has segmented the global lab supplies market based on product and region:

Find more research reports on Medical Devices Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web:https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Follow this link:
Lab Supplies Market Size Worth $49.6 Billion By 2027 | CAGR: 7.1%: Grand View Research, Inc. - PRNewswire

Patients across the Valley will soon feel more connected to their healthcare providers thanks to a mobile app changing the way clinical documentation and data entry are performed. Bayless Integrated Healthcare, an Arizona leader in integrating mental and physical health, has announced a partnership with Seattle-based healthcare technology company, Saykara, to implement this new technology in its eight locations across the Phoenix area.

The amount of data entry providers must do is on the rise due to additional requirements from insurance companies and government agencies. During a typical appointment, providers must simultaneously converse with patients while filling out electronic health records on a computer, which creates the feeling that providers are disengaged and multi-tasking, rather than offering their full attention. The data entry workload can be so great that providers often bring it home to complete during evening hours, contributing to fatigue and burnout.

The technology from Saykara reverses this trend by utilizing artificial intelligence to automate the challenging and time-consuming aspects of clinical documentation. This frees providers from their computers and restores quality facetime with patients.

Whole person wellness defines everything that we do at Bayless, says President and CEO of Bayless Integrated Healthcare, Justin Bayless. We know that the patient/provider connection is a deeply important part of that equation, and we continuously invest in the tools and technologies to improve that relationship. The more our patients feel heard during their appointments, and the more focused our providers are on them rather than data entry, the better our delivery of personalized medicine and the better our patient outcomes.

At the start of an appointment and with the patients consent, the Bayless provider simply accesses the Saykara mobile app from their iPhone. As the provider and patient engage, the app interprets the conversation and translates it to the data required for the electronic health record, reducing administrative busywork down to mere minutes, rather than hours.

Nobody wants to feel like theyre taking a back seat to administrative busywork when visiting a healthcare provider. This is when were all at our most vulnerable, says President and COO of Saykara, Graham Hughes, MD. By automating clinical documentation, our technology helps ensure that the time shared between a patient and provider is undistracted and that a trusting bond is forged.

The introduction of this technology at Bayless comes at a time when healthcare providers are increasingly reporting burnout amid the COVID-19 pandemic and may help alleviate some of the pressures they face. The result is reduced fatigue in providers, increased facetime with patients and a more trusting and deeply connected relationship between providers and the people in their care.

See the article here:
Bayless Integrated Healthcare deploys AI to improve patient care - AZ Big Media

Background:Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available.

Methods:The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study.

Discussion:This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System.

Trial registration:ClincalTrials.govNCT04147026. Registered on 31 October, 2019.

Keywords:Anti-TNF agents; Personalized medicine; Prediction models; Rheumatoid arthritis.

View original post here:
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response...

~Program to Focus on Advances and Breakthroughs in MS Research, Diagnostics and Technology~

~Special Press Events Planned to Give Media Access to Key Leaders & Late Breaker Investigators~

MIDDLETON, Wis., Aug. 31, 2020 /PRNewswire/ -- The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, will be held in a virtual format from September 11-13, 2020, with a special encore session featuring Late-Breaking News and a COVID-19 Session on September 26.

At this virtual conference MSVirtual2020 world class scientists, neurologists, clinicians and researchers from around the world will be presenting the latest research, clinical trial outcomes and technology and diagnostic advances in multiple sclerosis (MS).

Media registration, which is open to editors, reporters, producers, and active freelance writers and bloggers, will allow access to the full program including plenary sessions, invited speakers and platform presentations. Press Registration can be completed online here, or to expedite press registration, you can send a request directly to the Press Managers. They can be reached at: [emailprotected]and [emailprotected]. They are also available to arrange interviews with participating leaders, presenters and experts that you may wish to connect with.

The MSVirtual2020 program at a glance can be found here. Key topics will cover:

Keynote speakers will include:

MSVirtual2020 will be hosting a Newsroom on Newswise that will house various media materials including press releases, videos, infographics, bios & photos of leaders and speakers, and other assets. Newswise will also host a few Zoom press events for media only that will allow registered journalists to access and ask live questions to ACTRIMS-ECTRIMS leaders and late breaking investigators. The link to the MSVirtual2020 Newsroom is: here, or at the following link: https://www.newswise.com/home/actrims. The conference hashtag is: #MSVirtual2020.

MSVirtual2020 Press Events:

SOURCE Americas Committee for Treatment and Research in Multiple Sclerosis

Read more here:
The 8th Joint ACTRIMS-ECTRIMS Meeting - MSVirtual2020 - To be Held September 11-13 With A Special Encore Session Featuring COVID-19 & MS and Late...